AstraZeneca Cost Of Revenue vs Other Operating Expenses Analysis

AZN Stock

10,468 100.00 0.95%

AstraZeneca PLC financial indicator trend analysis is way more than just evaluating AstraZeneca PLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AstraZeneca PLC is a good investment. Please check the relationship between AstraZeneca PLC Cost Of Revenue and its Other Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AstraZeneca PLC Cost Of Revenue account and Other Operating Expenses. At this time, the significance of the direction appears to have very strong relationship.

The correlation between AstraZeneca PLC's Cost Of Revenue and Other Operating Expenses is 0.85. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of AstraZeneca PLC, assuming nothing else is changed. The correlation between historical values of AstraZeneca PLC's Cost Of Revenue and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of AstraZeneca PLC are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Cost Of Revenue i.e., AstraZeneca PLC's Cost Of Revenue and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on AstraZeneca PLC income statement and represents the costs associated with goods and services AstraZeneca PLC provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AstraZeneca PLC. It is also known as AstraZeneca PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from AstraZeneca PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AstraZeneca PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

The current year's Tax Provision is expected to grow to about 984.9 M, whereas Selling General Administrative is forecasted to decline to about 187.2 M.

	2021	2022	2023	2024 (projected)
Interest Expense	1.3B	1.3B	1.6B	1.7B
Depreciation And Amortization	4.1B	5.3B	4.9B	5.2B

Interest Expense Depreciation And Amortization

AstraZeneca PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Other Assets	Common Stock Total Equity
Total Assets		0.94	0.91	0.95	0.9	0.83	0.36	0.85	-0.24	0.04	0.33	0.99	0.48	0.18	0.7	0.9	-0.36	0.85	0.84	0.2	0.96	0.82	0.69	0.83	0.92	0.33
Short Long Term Debt Total	0.94		0.93	0.88	0.77	0.84	0.55	0.97	-0.52	-0.16	0.09	0.97	0.3	-0.08	0.49	0.77	-0.49	0.9	0.89	0.01	0.96	0.8	0.53	0.82	0.9	0.25
Other Current Liab	0.91	0.93		0.91	0.72	0.79	0.49	0.87	-0.4	-0.3	0.18	0.93	0.37	-0.05	0.46	0.76	-0.62	0.84	0.77	-0.07	0.94	0.85	0.46	0.8	0.93	0.2
Total Current Liabilities	0.95	0.88	0.91		0.87	0.77	0.4	0.78	-0.18	0.09	0.34	0.93	0.63	0.22	0.76	0.9	-0.31	0.72	0.71	0.24	0.9	0.9	0.64	0.9	0.89	0.23
Total Stockholder Equity	0.9	0.77	0.72	0.87		0.63	0.3	0.65	-0.03	0.24	0.41	0.85	0.57	0.31	0.87	0.83	-0.22	0.55	0.75	0.45	0.74	0.76	0.76	0.8	0.75	0.15
Property Plant And Equipment Net	0.83	0.84	0.79	0.77	0.63		0.42	0.76	-0.38	0.0	0.37	0.83	0.2	0.2	0.46	0.85	-0.26	0.85	0.75	0.13	0.88	0.58	0.75	0.64	0.84	0.56
Current Deferred Revenue	0.36	0.55	0.49	0.4	0.3	0.42		0.58	-0.69	-0.21	-0.16	0.36	-0.04	-0.26	0.17	0.2	-0.37	0.31	0.58	0.05	0.38	0.47	0.19	0.44	0.42	-0.09
Net Debt	0.85	0.97	0.87	0.78	0.65	0.76	0.58		-0.67	-0.25	-0.15	0.9	0.22	-0.31	0.34	0.63	-0.53	0.86	0.86	-0.12	0.89	0.76	0.34	0.78	0.81	0.11
Retained Earnings	-0.24	-0.52	-0.4	-0.18	-0.03	-0.38	-0.69	-0.67		0.51	0.56	-0.34	0.37	0.71	0.29	0.0	0.55	-0.45	-0.51	0.53	-0.36	-0.23	0.15	-0.37	-0.31	0.1
Accounts Payable	0.04	-0.16	-0.3	0.09	0.24	0.0	-0.21	-0.25	0.51		0.38	-0.08	0.49	0.66	0.61	0.27	0.82	-0.23	-0.1	0.7	-0.1	0.02	0.45	0.03	-0.12	0.19
Cash	0.33	0.09	0.18	0.34	0.41	0.37	-0.16	-0.15	0.56	0.38		0.22	0.23	0.92	0.56	0.57	0.18	0.15	0.08	0.5	0.25	0.06	0.77	0.11	0.34	0.64
Non Current Assets Total	0.99	0.97	0.93	0.93	0.85	0.83	0.36	0.9	-0.34	-0.08	0.22		0.42	0.05	0.59	0.86	-0.44	0.89	0.84	0.08	0.97	0.81	0.6	0.84	0.91	0.3
Non Currrent Assets Other	0.48	0.3	0.37	0.63	0.57	0.2	-0.04	0.22	0.37	0.49	0.23	0.42		0.35	0.75	0.53	0.23	0.12	0.17	0.43	0.36	0.73	0.35	0.51	0.37	-0.18
Cash And Short Term Investments	0.18	-0.08	-0.05	0.22	0.31	0.2	-0.26	-0.31	0.71	0.66	0.92	0.05	0.35		0.6	0.49	0.54	-0.03	-0.09	0.66	0.08	-0.02	0.69	0.01	0.14	0.6
Net Receivables	0.7	0.49	0.46	0.76	0.87	0.46	0.17	0.34	0.29	0.61	0.56	0.59	0.75	0.6		0.79	0.19	0.26	0.43	0.71	0.51	0.66	0.77	0.66	0.52	0.18
Common Stock Shares Outstanding	0.9	0.77	0.76	0.9	0.83	0.85	0.2	0.63	0.0	0.27	0.57	0.86	0.53	0.49	0.79		-0.06	0.71	0.6	0.4	0.85	0.67	0.83	0.77	0.79	0.54
Short Term Investments	-0.36	-0.49	-0.62	-0.31	-0.22	-0.26	-0.37	-0.53	0.55	0.82	0.18	-0.44	0.23	0.54	0.19	-0.06		-0.44	-0.45	0.54	-0.42	-0.36	0.1	-0.31	-0.46	0.22
Non Current Liabilities Total	0.85	0.9	0.84	0.72	0.55	0.85	0.31	0.86	-0.45	-0.23	0.15	0.89	0.12	-0.03	0.26	0.71	-0.44		0.8	-0.15	0.95	0.57	0.46	0.58	0.86	0.5
Inventory	0.84	0.89	0.77	0.71	0.75	0.75	0.58	0.86	-0.51	-0.1	0.08	0.84	0.17	-0.09	0.43	0.6	-0.45	0.8		0.08	0.82	0.66	0.56	0.61	0.83	0.2
Other Current Assets	0.2	0.01	-0.07	0.24	0.45	0.13	0.05	-0.12	0.53	0.7	0.5	0.08	0.43	0.66	0.71	0.4	0.54	-0.15	0.08		0.01	0.19	0.59	0.14	-0.01	0.15
Total Liab	0.96	0.96	0.94	0.9	0.74	0.88	0.38	0.89	-0.36	-0.1	0.25	0.97	0.36	0.08	0.51	0.85	-0.42	0.95	0.82	0.01		0.77	0.58	0.77	0.94	0.41
Property Plant And Equipment Gross	0.82	0.8	0.85	0.9	0.76	0.58	0.47	0.76	-0.23	0.02	0.06	0.81	0.73	-0.02	0.66	0.67	-0.36	0.57	0.66	0.19	0.77		0.4	0.8	0.75	-0.15
Total Current Assets	0.69	0.53	0.46	0.64	0.76	0.75	0.19	0.34	0.15	0.45	0.77	0.6	0.35	0.69	0.77	0.83	0.1	0.46	0.56	0.59	0.58	0.4		0.48	0.62	0.56
Short Term Debt	0.83	0.82	0.8	0.9	0.8	0.64	0.44	0.78	-0.37	0.03	0.11	0.84	0.51	0.01	0.66	0.77	-0.31	0.58	0.61	0.14	0.77	0.8	0.48		0.73	0.08
Other Assets	0.92	0.9	0.93	0.89	0.75	0.84	0.42	0.81	-0.31	-0.12	0.34	0.91	0.37	0.14	0.52	0.79	-0.46	0.86	0.83	-0.01	0.94	0.75	0.62	0.73		0.38
Common Stock Total Equity	0.33	0.25	0.2	0.23	0.15	0.56	-0.09	0.11	0.1	0.19	0.64	0.3	-0.18	0.6	0.18	0.54	0.22	0.5	0.2	0.15	0.41	-0.15	0.56	0.08	0.38

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Short Long Term Debt Total	18.2B	20.4B	30.8B	29.2B	28.6B	30.1B
Other Current Liab	12.9B	14.4B	16.0B	16.3B	19.8B	20.8B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.5B	32.1B
Total Stockholder Equity	13.1B	15.6B	39.3B	37.0B	39.1B	41.1B
Property Plant And Equipment Net	8.3B	8.9B	10.2B	9.4B	10.5B	6.8B
Net Debt	12.9B	12.5B	24.5B	23.1B	22.8B	23.9B
Retained Earnings	2.8B	5.3B	1.7B	(574M)	4.5B	8.5B
Accounts Payable	1.8B	2.4B	2.8B	2.6B	3.3B	2.8B
Cash	5.4B	7.8B	6.3B	6.2B	5.8B	4.7B
Non Current Assets Total	45.8B	47.2B	79.1B	73.9B	76.1B	79.9B
Non Currrent Assets Other	1.7B	1.1B	1.1B	1.1B	5.6B	5.9B
Cash And Short Term Investments	6.2B	8.0B	6.4B	6.4B	5.9B	5.8B
Net Receivables	3.6B	3.8B	6.0B	7.2B	8.4B	8.8B
Common Stock Shares Outstanding	1.3B	1.3B	1.4B	1.6B	1.6B	1.4B
Liabilities And Stockholders Equity	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Non Current Liabilities Total	28.7B	30.8B	43.5B	33.1B	31.4B	33.0B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	5.7B
Other Current Assets	2.6B	3.7B	4.8B	4.4B	5.4B	5.2B
Total Liab	46.8B	51.1B	66.1B	59.4B	62.0B	65.1B
Property Plant And Equipment Gross	8.3B	8.9B	10.2B	9.4B	19.1B	20.1B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	25.1B	15.3B
Short Term Debt	2.0B	2.4B	2.9B	6.5B	5.4B	5.7B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	5.0B
Other Stockholder Equity	7.8B	8.0B	35.1B	33.5B	33.3B	35.0B
Accumulated Other Comprehensive Income	(143M)	881M	111M	(1.6B)	(949M)	(996.5M)
Intangible Assets	20.8B	20.9B	42.4B	39.3B	38.1B	40.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	9.8B	6.7B
Long Term Debt	15.7B	17.5B	28.1B	23.0B	22.4B	11.3B
Good Will	11.7B	11.8B	20.0B	19.8B	20.0B	21.1B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	7.9B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(19.9B)	(20.9B)
Short Long Term Debt	1.8B	2.2B	1.7B	5.3B	5.1B	5.4B
Capital Surpluse	4.4B	4.4B	7.9B	8.0B	9.2B	6.4B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Other Information on Investing in AstraZeneca Stock

Balance Sheet is a snapshot of the financial position of AstraZeneca PLC at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Cost Of Revenue vs Other Operating Expenses Analysis

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Other Operating Expenses

AstraZeneca PLC fundamental ratios Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Short Long Term Debt Total
Total Liab	+ 0.97	Non Current Assets Total
Total Liab	+ 0.96	Total Assets
Total Liab	+ 0.96	Short Long Term Debt Total

Retained Earnings	- 0.69	Current Deferred Revenue
Retained Earnings	- 0.67	Net Debt
Short Term Investments	- 0.62	Other Current Liab
Short Term Investments	- 0.53	Net Debt
Retained Earnings	- 0.52	Short Long Term Debt Total
Inventory	- 0.51	Retained Earnings